TY  - JOUR

T1  - SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.2024.42.16_suppl.tps4623

PY  - 2024/06/01

AU  - Hussain SA

AU  - Loriot Y

AU  - de Velasco G

AU  - Necchi A

ED  - 

DO  - DOI: 10.1200/jco.2024.42.16_suppl.tps4623

PB  - American Society of Clinical Oncology (ASCO)

VL  - 42

IS  - 16_suppl

SP  - TPS4623

EP  - TPS4623

Y2  - 2024/12/21

ER  -